Hu002-MMAE

Hu002-MMAE is a preclinical-stage antibody-drug conjugate (ADC) targeting AXL (also known as UFO receptor tyrosine kinase). Developed by Fudan University, the Shanghai Institute of Materia Medica, Shanghai Pharma, and Mabwell, the drug consists of a humanized anti-AXL monoclonal antibody (Hu002) conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) via a novel disulfide-rebridging linker (BL20). AXL is a receptor tyrosine kinase overexpressed in various solid tumors, including non-small cell lung cancer (NSCLC), breast cancer, and glioma, where it promotes tumor cell migration, invasion, and metastasis. Upon binding to AXL on the surface of cancer cells, Hu002-MMAE is internalized, releasing MMAE to disrupt the microtubule network, induce cell cycle arrest, and trigger apoptosis. Preclinical studies have demonstrated potent in vitro cytotoxicity and robust in vivo anti-tumor efficacy in NSCLC and glioma models.

Other names

AXL-ADC (Hu002-MMAE)Hu002-BL20-MMAEHu-002-BL20-MMAEHu 002-BL20-MMAEmAb002c-BL20E-MMAEmAb-002c-BL20E-MMAEmAb 002c-BL20E-MMAEmAb002c-vcMMAEmAb-002c-vcMMAEmAb 002c-vcMMAE